GAMMAKED Drug Profile
✉ Email this page to a colleague
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- DrugPatentWatch analysis and company disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for GAMMAKED Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for GAMMAKED Derived from DrugPatentWatch Analysis and Company Disclosures
3) Low Certainty: US Patents for GAMMAKED Derived from Patent Text Search
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Grifols Therapeutics Llc | GAMMAKED, GAMUNEX-C | immune globulin injection (human) 10% caprylate/chromatography purified | Injection | 125046 | ⤷ Start Trial | 2035-11-09 | Patent claims search |
| Grifols Therapeutics Llc | GAMMAKED, GAMUNEX-C | immune globulin injection (human) 10% caprylate/chromatography purified | Injection | 125046 | ⤷ Start Trial | 2010-03-30 | Patent claims search |
| Grifols Therapeutics Llc | GAMMAKED, GAMUNEX-C | immune globulin injection (human) 10% caprylate/chromatography purified | Injection | 125046 | ⤷ Start Trial | 2021-03-22 | Patent claims search |
| Grifols Therapeutics Llc | GAMMAKED, GAMUNEX-C | immune globulin injection (human) 10% caprylate/chromatography purified | Injection | 125046 | ⤷ Start Trial | 2028-07-03 | Patent claims search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
International Patents for GAMMAKED
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Hungary | S1600053 | ⤷ Start Trial |
| European Patent Office | 2487161 | ⤷ Start Trial |
| European Patent Office | 1603541 | ⤷ Start Trial |
| European Patent Office | 3009517 | ⤷ Start Trial |
| South Korea | 20140004808 | ⤷ Start Trial |
| Taiwan | I496778 | ⤷ Start Trial |
| Slovenia | 2487166 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for GAMMAKED
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| CR 2015 00060 | Denmark | ⤷ Start Trial | PRODUCT NAME: COBICISTAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/13/830/001-002 20130527 |
| 2016/062 | Ireland | ⤷ Start Trial | PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND ATAZANAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR ATAZANAVIR SULFATE; REGISTRATION NO/DATE: EU/1/15/1025 20160713 |
| 132017000002735 | Italy | ⤷ Start Trial | PRODUCT NAME: COBICISTAT O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE O UN SOLVATO DELLO STESSO E DARUNAVIR O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE O UN SOLVATO DELLO STESSO, IN PARTICOLARE DARUNAVIR ETANOLATO(REZOLSTA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/967, 20141121 |
| CA 2020 00021 | Denmark | ⤷ Start Trial | PRODUCT NAME: COBICISTAT ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF, DARUNAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF, ISAER DARUNAVIR ETHANOLAT, OG EMTRICITABIN ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF; REG. NO/DATE: EU/1/17/1225 20170925 |
| 801 | Finland | ⤷ Start Trial | |
| CA 2015 00060 | Denmark | ⤷ Start Trial | PRODUCT NAME: COBICISTAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/13/830/001-002 20130527 |
| CA 2016 00031 | Denmark | ⤷ Start Trial | PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
